secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001493152-25-021980
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Interpace Biosciences Reports Q3 2025 Revenue of $8.8M, Thyroid Test Volume Up 12% YoY
--------------------------------------------------------------------------------

- Q3 2025 revenue $8.8M, up 22% pro forma vs prior year; operating income $1.1M
- Thyroid test volume grew 12% year-over-year to record levels; thyroid revenue $8.8M, up 22%
- Cash collections $10.0M in Q3; days sales outstanding reduced 22%
- Income from continuing operations $1.0M; adjusted EBITDA $1.3M
- Company completed transition to thyroid-only diagnostics; additional debt principal payments made

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315225021980/0001493152-25-021980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315225021980/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer